RNC Capital Management LLC Sells 190,748 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

RNC Capital Management LLC decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 29.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 458,670 shares of the biopharmaceutical company’s stock after selling 190,748 shares during the period. Gilead Sciences accounts for about 2.3% of RNC Capital Management LLC’s portfolio, making the stock its 20th biggest position. RNC Capital Management LLC’s holdings in Gilead Sciences were worth $42,367,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. nVerses Capital LLC bought a new stake in shares of Gilead Sciences during the 3rd quarter valued at about $25,000. HHM Wealth Advisors LLC boosted its holdings in Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 154 shares in the last quarter. Valued Wealth Advisors LLC boosted its holdings in Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 161 shares in the last quarter. YANKCOM Partnership bought a new position in Gilead Sciences in the fourth quarter worth approximately $28,000. Finally, Decker Retirement Planning Inc. bought a new position in Gilead Sciences in the fourth quarter worth approximately $29,000. Institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 142,180 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the transaction, the chief financial officer now owns 129,873 shares in the company, valued at approximately $12,626,253.06. This represents a 52.26 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jeffrey Bluestone sold 6,788 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the transaction, the director now owns 8,920 shares in the company, valued at $815,198.80. This trade represents a 43.21 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 572,824 shares of company stock worth $53,611,715 in the last 90 days. Company insiders own 0.29% of the company’s stock.

Gilead Sciences Stock Down 1.6 %

GILD opened at $98.04 on Friday. The company has a market cap of $122.18 billion, a P/E ratio of 1,089.33, a P/E/G ratio of 1.37 and a beta of 0.18. The business’s 50-day moving average price is $92.86 and its 200-day moving average price is $86.41. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $100.51.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter in the previous year, the business earned $2.29 earnings per share. The company’s quarterly revenue was up 7.0% on a year-over-year basis. On average, equities analysts expect that Gilead Sciences, Inc. will post 4.34 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on GILD shares. Mizuho raised their target price on Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. Sanford C. Bernstein started coverage on Gilead Sciences in a report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 target price on the stock. Cantor Fitzgerald restated a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a report on Wednesday, December 11th. BMO Capital Markets raised their target price on Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Finally, UBS Group raised their target price on Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Eleven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $98.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.